, Volume 8, Issue 6, pp 551–562 | Cite as

Fas—Beyond Death: A regenerative role for Fas in the nervous system

  • C. Lambert
  • A. M. Landau
  • J. Desbarats


Fas (CD95, APO-1), a member of the TNF superfamily, is a prototypical “death receptor” which transduces apoptotic signals in a variety of cell types. However, cell death is not the only possible outcome of Fas signalling. Fas engagement by Fas Ligand can also trigger proliferation or differentiation, promote tumour progression and angiogenesis, and induce cytokine secretion and integrin expression. Recently, we have reported that Fas engagement induces a potent regenerative response in sensory neurons in vitro, and enhances peripheral nerve regeneration in vivo. In contrast, other types of neurons, notably motoneurons, are acutely sensitive to Fas-induced apoptosis. Here, we review the literature on non-apoptotic Fas signalling pathways, and discuss the potential roles, molecular mechanisms, and regulators of Fas signalling in the nervous system.

Fas nervous system neurite outgrowth neuron neurodegeneration regeneration 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169: 1747–1756.Google Scholar
  2. 2.
    Trauth BC, Klas C, Peters AM, et al. Monoclonal antibodymediated tumor regression by induction of apoptosis. Science 1989; 245: 301–305.Google Scholar
  3. 3.
    Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferative disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314–317.Google Scholar
  4. 4.
    Brunner T, Mogil RJ, LaFace D, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995; 373: 342–345.Google Scholar
  5. 5.
    Ju ST, Panka DJ, Cui H, et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373 345–348.Google Scholar
  6. 6.
    Dhein J, Walczak H, Baumler C, Debatin K-M, Krammer PH. Autocrine T-cell suicide mediated by APO-1/ (Fas/CD95). Nature 1995; 373: 438–440.Google Scholar
  7. 7.
    Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449–1456.Google Scholar
  8. 8.
    Fraser A, Evan G. A license to kill. Cell 1996; 85: 781–784.Google Scholar
  9. 9.
    Nagata S. Apoptosis by death factor. Cell 1997; 88: 355–365.Google Scholar
  10. 10.
    Sharma K, Wang RX, Zhang LY, et al. Death the Fas way: Regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther 2000; 88: 333–347.Google Scholar
  11. 11.
    Owen-Schaub LB, Meterissian S, Ford RJ. Fas/APO-1 expression and function on malignant cells of hematologic and non-hematologic origin. J Immunotherapy 1993; 14: 234–241.Google Scholar
  12. 12.
    Alderson MR, Armitage RJ, Maraskovsky E, et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993; 178: 2231–2235.Google Scholar
  13. 13.
    Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene 1998; 17: 3261–3270.Google Scholar
  14. 14.
    Chan FK, Chun HJ, Zheng L, et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288: 2351–2354.Google Scholar
  15. 15.
    Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW. NMR structure and mutagenesis of the Fas (APO-1/ CD95) death domain. Nature 1996; 384: 638–641.Google Scholar
  16. 16.
    Strasser A, Newton K. FADD/MORT1, a signal transducer that can promote cell death or cell growth. Int J Biochem Cell Biol 1999; 31: 533–537.Google Scholar
  17. 17.
    Michaelson JS. The Daxx enigma. Apoptosis 2000; 5: 217–220.Google Scholar
  18. 18.
    Stanger BZ, Leder P, Lee TH, Kim E, Seed B. RIP:Anovel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 1995; 81: 513–523.Google Scholar
  19. 19.
    Sato T, Irie S, Kitada S, Reed JC. FAP-1: A protein tyrosine phosphatase that associates with Fas. Science 1995; 268: 411–415.Google Scholar
  20. 20.
    Wajant H. The Fas signaling pathway: More than a paradigm. Science 2002; 296: 1635–1636.Google Scholar
  21. 21.
    Nagata S. Fas-induced apoptosis. Intern Med 1998; 37: 179–181.Google Scholar
  22. 22.
    Varfolomeev EE, Schuchmann M, Luria V, et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 1998; 9: 267–276.Google Scholar
  23. 23.
    Chang HY, Yang X, Baltimore D. Dissecting Fas signaling with an altered-specificity death-domain mutant: Requirement of FADD binding for apoptosis but not Jun N-terminal kinase activation. Proc Natl Acad Sci USA 1999; 96: 1252–1256.Google Scholar
  24. 24.
    Wajant H, Johannes FJ, Haas E, et al. Dominant-negative FADD inhibits TNFR60-, Fas/Apo1-and TRAIL-R/Apo2-mediated cell death but not gene induction. Curr Biol 1998; 8: 113–116.Google Scholar
  25. 25.
    Yeh WC, Pompa JL, McCurrach ME, et al. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 1998; 279: 1954–1958.Google Scholar
  26. 26.
    Zhang J, Cado D, Chen A, Kabra NH, Winoto A. Fasmediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 1998; 392: 296–300.Google Scholar
  27. 27.
    Hueber AO, Zornig M, Bernard AM, Chautan M, Evan G. A dominant negative Fas-associated death domain protein mutant inhibits proliferation and leads to impaired calcium mobilization in both T-cells and fibroblasts. J Biol Chem 2000; 275: 10453–10462.Google Scholar
  28. 28.
    Mack A, Hacker G. Inhibition of caspase or FADD function blocks proliferation but not MAP kinase-activation and interleukin-2-production during primary stimulation of T cells. Eur J Immunol 2002; 32: 1986–1992.Google Scholar
  29. 29.
    Newton K, Harris AW, Bath ML, Smith KG, Strasser A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. Embo J 1998; 17: 706–718.Google Scholar
  30. 30.
    Zornig M, Hueber AO, Evan G. p53-dependent impairment of T-cell proliferation in FADD dominant-negative transgenic mice. Curr Biol 1998; 8: 467–470.Google Scholar
  31. 31.
    Hua ZC, Sohn SJ, Kang C, Cado D, Winoto A. A function of Fas-associated death domain protein in cell cycle progression localized to a single amino acid at its C-terminal region. Immunity 2003; 18: 513–521.Google Scholar
  32. 32.
    Thome M, Tschopp J. Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol 2001; 1: 50–58.Google Scholar
  33. 33.
    Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190–195.Google Scholar
  34. 34.
    Yeh WC, Itie A, Elia AJ, et al. Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 2000; 12: 633–642.Google Scholar
  35. 35.
    Kataoka T, Budd RC, Holler N, et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol 2000; 10: 640–648.Google Scholar
  36. 36.
    Derkinderen P, Enslen H, Girault JA. The ERK/MAP-kinases cascade in the nervous system. Neuroreport 1999; 10: R24–R34.Google Scholar
  37. 37.
    Aoudjit F, Vuori K. Matrix attachment regulates Fas-induced apoptosis in endothelial cells.Arole for c-flip and implications for anoikis. J Cell Biol 2001; 152: 633–644.Google Scholar
  38. 38.
    Ko YG, Kang YS, Park H, et al. Apoptosis signal-regulating kinase 1 controls the proapoptotic function of deathassociated protein (Daxx) in the cytoplasm. J Biol Chem 2001; 276: 39103–39106.Google Scholar
  39. 39.
    Yang X, Khosravi-Far R, Chang HY, Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 1997; 89: 1067–1076.Google Scholar
  40. 40.
    Torii S, Egan DA, Evans RA, Reed JC. Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs). Embo J 1999; 18: 6037–6049.Google Scholar
  41. 41.
    Michaelson JS, Bader D, Kuo F, Kozak C, Leder P. Loss of Daxx, a promiscuously interacting protein, results in extensive apoptosis in early mouse development. Genes Dev 1999; 13: 1918–1923.Google Scholar
  42. 42.
    Yu PW, Huang BC, Shen M, et al. Identification of RIP3, a RIP-like kinase that activates apoptosis and NFkappaB. Curr Biol 1999; 9: 539–542.Google Scholar
  43. 43.
    Meylan E, Martinon F, Thome M, Gschwendt M, Tschopp J. RIP4 (DIK/PKK), a novel member of the RIP kinase family, activates NF-kappa B and is processed during apoptosis. EMBO Rep 2002; 3: 1201–1208.Google Scholar
  44. 44.
    Kelliher MA, Grimm S, Ishida Y, et al. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 1998; 8: 297–303.Google Scholar
  45. 45.
    Kasof GM, Prosser JC, Liu D, Lorenzi MV, Gomes BC. The RIP-like kinase, RIP3, induces apoptosis and NF-kappaB nuclear translocation and localizes to mitochondria. FEBS Lett 2000; 473: 285–291.Google Scholar
  46. 46.
    Holler N, Zaru R, Micheau O, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1: 489–495.Google Scholar
  47. 47.
    Thome M, Hofmann K, Burns K, et al. Identification of CARDIAK, a RIP-like kinase that associates with caspase-1. Curr Biol 1998; 8: 885–888.Google Scholar
  48. 48.
    Varfolomeev EE, Boldin MP, Goncharov TM, Wallach D. A potential mechanism of “cross-talk” between the p55 tumor necrosis factor receptor and Fas/APO1: Proteins binding to the death domains of the two receptors also bind to each other. J Exp Med 1996; 183: 1271–1275.Google Scholar
  49. 49.
    Hu WH, Johnson H, Shu HB. Activation of NF-kappaB by FADD, Casper, and caspase-8. J Biol Chem 2000; 275: 10838–10844.Google Scholar
  50. 50.
    Kim JW, Choi EJ, Joe CO. Activation of death-inducing signaling complex (DISC) by pro-apoptotic C-terminal fragment of RIP. Oncogene 2000; 19: 4491–4499.Google Scholar
  51. 51.
    Cusson N, Oikemus S, Kilpatrick ED, Cunningham L, Kelliher M. The death domain kinase RIP protects thymocytes from tumor necrosis factor receptor type 2-induced cell death. J Exp Med 2002; 196: 15–26.Google Scholar
  52. 52.
    Navas TA, Baldwin DT, Stewart TA. RIP2 is a Raf1-activated mitogen-activated protein kinase kinase. J Biol Chem 1999; 274: 33684–33690.Google Scholar
  53. 53.
    Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 1997; 385: 540–544.Google Scholar
  54. 54.
    Pazdernik NJ, Donner DB, Goebl MG, Harrington MA. Mouse receptor interacting protein 3 does not contain a caspase-recruiting or a death domain but induces apoptosis and activates NF-kappaB. Mol Cell Biol 1999; 19: 6500–6508.Google Scholar
  55. 55.
    Li X, Stark GR. NFkappaB-dependent signaling pathways. Exp Hematol 2002; 30: 285–296.Google Scholar
  56. 56.
    Duan H, Dixit VM. RAIDDis a new 'death' adaptor molecule. Nature 1997; 385: 86–89.Google Scholar
  57. 57.
    Cerretti DP, Kozlosky CJ, Mosley B, et al. Molecular cloning of the interleukin-1 beta converting enzyme. Science 1992; 256: 97–100.Google Scholar
  58. 58.
    Adachi M, Watanabe-Fukunaga R, Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci USA 1993; 90: 1756–1760.Google Scholar
  59. 59.
    Kimura M, Matsuzawa A. Autoimmunity in mice bearing A novel mutant gene. Int Rev Immunol 1994; 11: 193–210.Google Scholar
  60. 60.
    Eberstadt M, Huang B, Olejniczak ET, Fesik SW. The lymphoproliferation mutation in Fas locally unfolds the Fas death domain. Nat Struct Biol 1997; 4: 983–985.Google Scholar
  61. 61.
    Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nature Medicine 2000; 6: 920–923.Google Scholar
  62. 62.
    Desbarats J, Birge RB, Mimouni-Rongy M, et al. Fas engagement induces neurite growth via ERK activation and p35 upregulation. Nature Cell Biol 2003; 5: 118–125.Google Scholar
  63. 63.
    Adachi M, Suematsu S, Suda T, et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nature Genet 1995; 11: 294–300.Google Scholar
  64. 64.
    Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 2000; 6: 920–923.Google Scholar
  65. 65.
    Jelaska A, Korn JH. Anti-Fas induces apoptosis and proliferation in human dermal fibroblasts: Differences between foreskin and adult fibroblasts. J Cell Physiol 1998; 175: 19–29.Google Scholar
  66. 66.
    Freiberg RA, Spencer DM, Choate KA, et al. Fas signal transduction triggers either proliferation or apoptosis in human fibroblasts. J Invest Dermatol 1997; 108: 215–219.Google Scholar
  67. 67.
    Aggarwal BB, Singh S, LaPushin R, Totpal K. Fas antigen signals proliferation of normal human diploid fibroblast and its mechanism is different from tumor necrosis factor receptor. FEBS Lett 1995; 364: 5–8.Google Scholar
  68. 68.
    Alderson MR, Tough TW, Braddy S, et al. Regulation of apoptosis and T cell activation by Fas-specific mAb. Int Immunol 1994; 6: 1799–1806.Google Scholar
  69. 69.
    Desbarats J, Wade T, Wade WF, Newell MK. Dichotomy between naïve and memory CD4+ T cell responses to Fas (CD95) engagement. Proc Natl Acad Sci USA 1999; 96: 8104–8109.Google Scholar
  70. 70.
    Shinohara H, Yagita H, Ikawa Y, Oyaizu N. Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase. Cancer Res 2000; 60: 1766–1772.Google Scholar
  71. 71.
    Husain N, Chiocca EA, Rainov N, Louis DN, Zervas NT. Coexpression of Fas and Fas Ligand in malignant glial tumors and cell lines. Acta Neuropathol 1998; 95: 287–290.Google Scholar
  72. 72.
    Borset M, Hjorth-Hansen H, Johnsen AC, et al. Apoptosis, proliferation and NF-kappaB activation induced by agonistic Fas antibodies in the human myeloma cell line OH-2: Ampli-fication of Fas-mediated apoptosis by tumor necrosis factor. Eur J Haematol 1999; 63: 345–353.Google Scholar
  73. 73.
    Lens SM, Kataoka T, Fortner KA, et al. The caspase 8 inhibitor c-FLIP(L) modulates T-cell receptor-induced proliferation but not activation-induced cell death of lymphocytes. Mol Cell Biol 2002; 22: 5419–5433.Google Scholar
  74. 74.
    Kennedy NJ, Kataoka T, Tschopp J, Budd RC. Caspase activation is required for T cell proliferation. J Exp Med 1999; 190: 1891–1896.Google Scholar
  75. 75.
    Ahn JH, Park SM, Cho HS, et al. Non-apoptotic signaling pathways activated by soluble Fas ligand in serum-starved human fibroblasts. Mitogen-activated protein kinases and NFkappaB-dependent gene expression. J Biol Chem 2001; 276: 47100–47106.Google Scholar
  76. 76.
    Miwa K, Asano M, Horai R, et al. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998; 4: 1287–1292.Google Scholar
  77. 77.
    Rosenwasser LJ. Biologic activities of IL-1 and its role in human disease. J Allergy Clin Immunol 1998; 102: 344–350.Google Scholar
  78. 78.
    O'Connor JJ, Coogan AN. Actions of the pro-inflammatory cytokine IL-1 beta on central synaptic transmission. Exp Physiol 1999; 84: 601–614.Google Scholar
  79. 79.
    Juttler E, Tarabin V, Schwaninger M. Interleukin-6 (IL-6): A possible neuromodulator induced by neuronal activity. Neuroscientist 2002; 8: 268–275.Google Scholar
  80. 80.
    Harada A, Sekido N, Akahoshi T, et al. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol 1994; 56: 559–564.Google Scholar
  81. 81.
    Choi C, Gillespie GY, VanWagoner NJ, Benveniste EN. Fas engagement increases expression of interleukin-6 in human glioma cells. J Neurooncol 2002; 56: 13–19.Google Scholar
  82. 82.
    Benigni F, Sacco S, Aloe L, Ghezzi P. Intracerebroventricular injection of anti-Fas activates the hypothalamus-pituitaryadrenal axis and induces peripheral interleukin-6 and serum amyloid A in mice: Comparison with other ligands of the tumor necrosis factor/nerve growth factor receptor superfamily. Am J Pathol 1998; 153: 1377–1381.Google Scholar
  83. 83.
    Abreu-Martin MT, Vidrich A, Lynch DH, Targan SR. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. J Immunol 1995; 155: 4147–4154.Google Scholar
  84. 84.
    Sekine C, Yagita H, Kobata T, et al. Fas-mediated stimulation induces IL-8 secretion by rheumatoid arthritis synoviocytes independently of CPP32-mediated apoptosis. Biochem Biophys Res Commun 1996; 228: 14–20.Google Scholar
  85. 85.
    O'Brien D, O'Connor T, Shanahan F, O'Connell J. Activation of the p38 MAPK and ERK1/2 pathways is required for Fasinduced IL-8 production in colonic epithelial cells. Ann NY Acad Sci 2002; 973: 161–165.Google Scholar
  86. 86.
    Schaub FJ, Han DK, Liles WC, et al. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat Med 2000; 6: 790–796.Google Scholar
  87. 87.
    Jarad G, Wang B, Khan S, et al. Fas activation induces renal tubular epithelial cell beta 8 integrin expression and function in the absence of apoptosis. J Biol Chem 2002; 277: 47826–47833.Google Scholar
  88. 88.
    Biancone L, Martino AD, Orlandi V, et al. Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J Exp Med 1997; 186: 147–152.Google Scholar
  89. 89.
    Reichmann E. The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol 2002; 12: 309–315.Google Scholar
  90. 90.
    Osaki M, Kase S, Kodani I, et al. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: Correlation with proliferation and apoptosis. Gastric Cancer 2001; 4: 198–205.Google Scholar
  91. 91.
    Gerharz CD, Ramp U, Dejosez M, et al. Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: An important factor for evasion from negative growth control. Lab Invest 1999; 79: 1521–1534.Google Scholar
  92. 92.
    Yakirevich E, Maroun L, Cohen O, et al. Apoptosis, proliferation, and Fas (APO-1, CD95)/Fas ligand expression in medullary carcinoma of the breast. J Pathol 2000; 192: 166–173.Google Scholar
  93. 93.
    Ungfroren H, Voss M, Jansen M, et al. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 1998; 58: 1741–1749.Google Scholar
  94. 94.
    Bodey B, Bodey B, Jr, Siegel SE, Kaiser HE. Immunocytochemical detection of leukocyte-associated and apoptosisrelated antigen expression in childhood brain tumors. Crit Rev Oncol Hematol 2001; 39: 3–16.Google Scholar
  95. 95.
    Xerri L, Devilard E, Hassoun J, Haddad P, Birg F. Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-madiated apoptosis. Leukemia 1997; 11: 1868–1877.Google Scholar
  96. 96.
    Donin N, Kay S, Sinai J, et al. Apoptosis and cell proliferation capacity in AKR lymphoma malignancy variants. Cancer Invest 2000; 18: 702–714.Google Scholar
  97. 97.
    Nat R, Radu E, Regalia T, Popescu LM. Apoptosis in human embryo development: 3. Fas-induced apoptosis in brain primary cultures. J Cell Mol Med 2001; 5: 417–428.Google Scholar
  98. 98.
    Park C, Sakamaki K, Tachibana O, et al. Expression of fas antigen in the normal mouse brain. Biochem Biophys Res Commun 1998; 252: 623–638.Google Scholar
  99. 99.
    Raoul C, Henderson CE, Pettmann B. Programmed cell death of embryonic motoneurons triggered through the Fas death receptor. J Cell Biol 1999; 147: 1049–1062.Google Scholar
  100. 100.
    Raoul C, Estevez AG, Nishimune H, et al. Motoneuron death triggered by a specific pathway downstream of Fas. potentiation by ALS-linked SOD1 mutations. Neuron 2002; 35: 1067–1083.Google Scholar
  101. 101.
    Casha S, Yu WR, Fehlings MG. Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat. Neuroscience 2001; 103: 203–218.Google Scholar
  102. 102.
    Choi C, Park JY, Lee J, et al. Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-alpha, or IFN-gamma. J Immunol 1999; 162: 1889–1895.Google Scholar
  103. 103.
    Bechmann I, Lossau S, Steiner B, et al. Reactive astrocytes upregulate Fas (CD95) and Fas ligand (CD95L) expression but do not undergo programmed cell death during the course of anterograde degeneration. Glia 2000; 32: 25–41.Google Scholar
  104. 104.
    Spanaus KS, Schlapbach R, Fontana A. TNF-alpha and IFN-gamma render microglia sensitive to Fas ligand-induced apoptosis by induction of Fas expression and down-regulation of Bcl-2 and Bcl-xL. Eur J Immunol 1998; 28: 4398–4408.Google Scholar
  105. 105.
    Wohlleben G, Ibrahim S, Schmidt J, et al. Regulation of Fas and FasL expression on rat Schwann cells. Glia 2000; 30: 373–381.Google Scholar
  106. 106.
    Pettmann B, Henderson CE. Killer wiles: Growing interest in Fas. Nat Cell Biol 2003; 5: 91–92.Google Scholar
  107. 107.
    Hess DC, Taormina M, Thompson J, et al. Cognitive and neurological deficits in the MRL/lpr mouse: A clinicopathologic study. J Rheumatol 1993; 20: 610–617.Google Scholar
  108. 108.
    Hikawa N, Kiuchi Y, Maruyama T, Takenaka T. Delayed neurite regeneration and its improvement by nerve growth factor (NGF) in dorsal root ganglia from MRL-lpr/lpr mice in vitro. J Neurol Sci 1997; 149: 13–17.Google Scholar
  109. 109.
    Sakic B, Szechtman H, Denburg J, et al. Progressive atrophy of pyramidal neuron dendrites in autoimmune MRL-lpr mice. J Neuroimmunol 1998; 87: 162–170.Google Scholar
  110. 110.
    Ruckenstein MJ, Sarwar A, Hu L, Shami H, Marion TN. Effects of immunosupression on the development of cochlear disease in the MRL-Fas (lpr) mouse. Laryngoscope 1999; 109: 626–630.Google Scholar
  111. 111.
    Ruckenstein MJ, Milburn M, Hu L. Strial dysfunction in the MRL-Fas mouse. Otolaryngol Head Neck Surg 1999; 121: 452–456.Google Scholar
  112. 112.
    Harada T, Morooka T, Ogawa S, Nishida E. ERK induces p35, a neuron-specific activator of Cdk5, through induction of Egr1. Nat Cell Biol 2001; 3: 453–459.Google Scholar
  113. 113.
    Nikolic M, Dudek H, Kwon YT, Ramos YF, Tsai LS. The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev 1996; 10: 816–825.Google Scholar
  114. 114.
    Tsai LS, Dellale I, Caviness VSS, Chae T, Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 1994; 371: 419–423.Google Scholar
  115. 115.
    Pang L, Sawada T, Decker SJ, Saltiel AR. Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem 1995; 270: 13585–13588.Google Scholar
  116. 116.
    Patapoutian A, Reichardt LF. Trk receptors: Mediators of neurotrophin action. Curr Opin Neurobiol 2001; 11: 272–280.Google Scholar
  117. 117.
    Cui Q, Tang LS, Hu B, So KF, Yip HK. Expression of trkA, trkB, and trkC in injured and regenerating retinal ganglion cells of adult rats. Invest Ophthalmol Vis Sci 2002; 43: 1954–1964.Google Scholar
  118. 118.
    Qiao L, Vizzard MA. Up-regulation of tyrosine kinase (Trka, Trkb) receptor expression and phosphorylation in lumbosacral dorsal root ganglia after chronic spinal cord (T8-T10) injury. J Comp Neurol 2002; 449: 217–230.Google Scholar
  119. 119.
    Shin SW, Park JW, Suh MH, Suh SI, Choe BK. Persistent expression of Fas/FasL mRNA in the mouse hippocampus after a single NMDA injection. J Neurochem 1998; 71: 1773–1776.Google Scholar
  120. 120.
    de la Monte SM, Sohn YK, Wands JR. Correlates of p53-and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 1997; 152: 73–83.Google Scholar
  121. 121.
    Puig B, Ferrer I. Cell death signaling in the cerebellum in Creutzfeldt-Jakob disease. Acta Neuropathol (Berl) 2001; 102: 207–215.Google Scholar
  122. 122.
    Facchinetti F, Furegato S, Terrazzino S, Leon A. H(2)O(2) induces upregulation of Fas and Fas ligand expression in NGF-differentiated PC12 cells: Modulation by cAMP. J Neurosci Res 2002; 69: 178–188.Google Scholar
  123. 123.
    Vogt M, Bauer MK, Ferrari D, Schulze-Osthoff K. Oxidative stress and hypoxia/reoxygenation trigger CD95 (APO-1/Fas) ligand expression in microglial cells. FEBS Lett 1998; 429: 67–72.Google Scholar
  124. 124.
    de la Monte SM, Neely TR, Cannon J, Wands JR. Oxidative stress and hypoxia-like injury cause Alzheimer-type molecular abnormalities in central nervous system neurons. Cell Mol Life Sci 2000; 57: 1471–1481.Google Scholar
  125. 125.
    Northington FJ, Ferriero DM, Martin LJ. Neurodegeneration in the thalamus following neonatal hypoxia-ischemia is programmed cell death. Dev Neurosci 2001; 23: 186–191.Google Scholar
  126. 126.
    Northington FJ, Ferriero DM, Flock DL, Martin LJ. Delayed neurodegeneration in neonatal rat thalamus after hypoxia-ischemia is apoptosis. J Neurosci 2001; 21: 1931–1938.Google Scholar
  127. 127.
    Felderhoff-Mueser U, Taylor DL, Greenwood K, et al. Fas/CD95/APO-1 can function as a death receptor for neuronal cells in vitro and in vivo and is upregulated following cerebral hypoxic-ischemic injury to the developing rat brain. Brain Pathol 2000; 10: 17–29.Google Scholar
  128. 128.
    Harrison DC, Davis RP, Bond BC, et al. Caspase mRNA expression in a rat model of focal cerebral ischemia. Brain Res Mol Brain Res 2001; 89: 133–146.Google Scholar
  129. 129.
    van Landeghem FK, Felderhoff-Mueser U, Moysich A, et al. Fas (CD95/Apo-1)/Fas ligand expression in neonates with pontosubicular neuron necrosis. Pediatr Res 2002; 51: 129–135.Google Scholar
  130. 130.
    Morita-Fujimura Y, Fujimura M, Yoshimoto T, Chan PH. Superoxide during reperfusion contributes to caspase-8 expression and apoptosis after transient focal stroke. Stroke 2001; 32: 2356–2361.Google Scholar
  131. 131.
    Jin K, Graham SH, Mao X, et al. Fas (CD95) may mediate delayed cell death in hippocampal CA1 sector after global cerebral ischemia. J Cereb Blood Flow Metab 2001; 21: 1411–1421.Google Scholar
  132. 132.
    Matsushita K, Wu Y, Qiu J, et al. Fas receptor and neuronal cell death after spinal cord ischemia. J Neurosci 2000; 20: 6879–6887.Google Scholar
  133. 133.
    Martin-Villalba A, Herr I, Jeremias I, et al. CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci 1999; 19: 3809–3817.Google Scholar
  134. 134.
    Martin-Villalba A, Hahne M, Kleber S, et al. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ 2001; 8: 679–686.Google Scholar
  135. 135.
    Nitobe J, Yamaguchi S, Okuyama M, et al. Reactive oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas-mediated apoptosis in cardiac myocytes. Cardiovasc Res 2003; 57: 119–128.Google Scholar
  136. 136.
    Giardina C, Boulares H, Inan MS. NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: The role of reactive oxygen species. Biochim Biophys Acta 1999; 1448: 425–438.Google Scholar
  137. 137.
    Xiong ZQ, McNamara JO. Fas(t) balls and Lou Gehrig disease. Aclue to selective vulnerability of motor neurons? Neuron 2002; 35: 1011–1013.Google Scholar
  138. 138.
    Danielson SR, Wong A, Carelli V, et al. Cells bearing mutations causing Leber's hereditary optic neuropathy are sensitized to Fas-Induced apoptosis. J Biol Chem 2002; 277: 5810–5815.Google Scholar
  139. 139.
    Wosik K, Becher B, Ezman A, Nalbantoglu J, Antel JP. Caspase 8 expression and signaling in Fas injury-resistant human fetal astrocytes. Glia 2001; 33: 217–224.Google Scholar
  140. 140.
    Teitz T, Lahti JM, Kidd VJ. Aggressive childhood neuroblastomas do not express caspase-8: An important component of programmed cell death. J Mol Med 2001; 79: 428–436.Google Scholar
  141. 141.
    Kanda D, Takagi H, Toyoda M, et al. Transforming growth factor alpha protects against Fas-mediated liver apoptosis in mice. FEBS Lett 2002; 519: 11–15.Google Scholar
  142. 142.
    Mitsunaka H, Dobashi H, Sato M, et al. Growth hormone prevents Fas-induced apoptosis in lymphocytes through modulation of Bcl-2 and caspase-3. Neuroimmunomodulation 2001; 9: 256–262.Google Scholar
  143. 143.
    Steinbach JP, Supra P, Huang HJ, Cavenee WK, Weller M. CD95-mediated apoptosis of human glioma cells: Modulation by epidermal growth factor receptor activity. Brain Pathol 2002; 12: 12–20.Google Scholar
  144. 144.
    Chen W, Jin W, Tian H, et al. Requirement for transforming growth factor beta1 in controlling T cell apoptosis. J Exp Med 2001; 194: 439–453.Google Scholar
  145. 145.
    Chodon T, Sugihara T, Igawa HH, Funayama E, Furukawa H. Keloid-derived fibroblasts are refractory to Fas-mediated apoptosis and neutralization of autocrine transforming growth factor-beta1 can abrogate this resistance. Am J Pathol 2000; 157: 1661–1669.Google Scholar
  146. 146.
    Suzuki A, Hayashida M, Kawano H, et al. Hepatocyte growth factor promotes cell survival from fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression. Hepatology 2000; 32: 796–802.Google Scholar
  147. 147.
    Kazama H, Yonehara S. Oncogenic K-Ras and basic fibroblast growth factor prevent Fas-mediated apoptosis in fibroblasts through activation of mitogen-activated protein kinase. J Cell Biol 2000; 148: 557–566.Google Scholar
  148. 148.
    Gibson S, Tu S, Oyer R, Anderson SM, Johnson GL. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem 1999; 274: 17612–17618.Google Scholar
  149. 149.
    Haeffner A, Deas O, Mollereau B, et al. Growth hormone prevents human monocytic cells from Fas-mediated apoptosis by up-regulating Bcl-2 expression. Eur J Immunol 1999; 29: 334–344.Google Scholar
  150. 150.
    Kosai K, Matsumoto K, Nagata S, Tsujimoto Y, Nakamura T. Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor. Biochem Biophys Res Commun 1998; 244: 683–690.Google Scholar
  151. 151.
    Boehme SA, Lio FM, Maciejewski-Lenoir D, Bacon KB, Conlon PJ. The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J Immunol 2000; 165: 397–403.Google Scholar
  152. 152.
    Wilson D, Alessandrini A, Budd R. MEK1 activation rescues Jurkat T cells from Fas-induced apoptosis. Cell Immunol 1999; 194: 67–77.Google Scholar
  153. 153.
    Holmstrom T, Schmitz I, Soderstrom T, et al. MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly. EMBO J 2000; 19: 5418–5428.Google Scholar
  154. 154.
    Tran SE, Holmstrom TH, Ahonen M, Kahari VM, Eriksson JE. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem 2001; 276: 16484–16490.Google Scholar
  155. 155.
    Moalem G, Leibowitz-Amit R, Yoles E, et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nature Med 1999; 5: 49–55.Google Scholar
  156. 156.
    Schwartz M, Moalem G, Leibowitz-Amit R, Cohen IR. Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci 1999; 22: 295–299.Google Scholar
  157. 157.
    Hensley K, Robinson KA, Gabbita SP, Salsman S, Floyd RA. Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med 2000; 28: 1456–1462.Google Scholar
  158. 158.
    Ertel W, Keel M, Stocker R, et al. Detectable concentrations of Fas ligand in cerebrospinal fluid after severe head injury. J Neuroimmunol 1997; 80: 93–96.Google Scholar
  159. 159.
    Martinez M, Fernandez-Vivancos E, Frank A, De la Fuente M, Hernanz A. Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer's disease. Relationship with IL-6 concentrations. Brain Res 2000; 869: 216–219.Google Scholar
  160. 160.
    Mogi M, Harada M, Kondo T, et al. The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neurosci Lett 1996; 220: 195–198.Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  1. 1.Department of PhysiologyMcGill UniversityMontréalCanada

Personalised recommendations